Abstract 15P
Background
Estrogen plays a pivotal role in the development of breast cancer. Previous studies have shown that estrogen enhances cell proliferation via regulating its target gene expression in human breast cancer MCF-7 cell line. Although the effect of estrogen on the carcinogenesis in breast, the effects of pregnenolone (PG), an inactive precursor of estrogen, on MCF-7 cells or breast cancer have not been adequately explored. PG is a precursor in the biosynthesis of most of the steroid hormones containing estrogen. This investigation aimed to evaluate the effects of PG on cell proliferation and cell cycle-related protein expression.
Methods
We used Michigan Cancer Foundation-7 cell (MCF-7 cell) line, to assess the impact of PG on the carcinogenicity of breast cancer cells. We examined cell proliferation, survival rate and mobility using Bromodeoxyuridine, MTT assay and western blot. To reveal the mechanism of PG, we performed RNA seq after treatment of PG in the MCF-7 cells and transfection using siRNA of estrogen receptor and ERE luciferase vector.
Results
PG increased cell proliferation, viability, mobility, and the expression of proteins associated with the cell cycle, such as CDK2, CDK4, and Cyclin D1. We elucidated the carcinogenic mechanism of PG. Through protein-ligand docking energy analysis, we measured the affinity of PG for estrogen receptors (ERs), showing a high affinity for ERα similar to E2. When treated with cyanine 5-conjugated with PG (Cy5-PG), we observed that PG entered the cells within five minutes. Then, activated ERα entered the nucleus, bound to ERE-promoters, and significantly increased the expression of target genes associated with cell proliferation and carcinogenicity, such as pS2 and Ki-67. These results indicate that PG increases the expression of target genes through ERα and thereby affects the carcinogenicity of breast cancer cells.
Conclusions
Our results demonstrate that PG can have a significant impact on the proliferation and migration of ERα-positive breast cancer cells through ERα. Furthermore, the sustained high concentration of PG, unlike E2 which rapidly decreases after menopause, is strongly associated with the development of breast cancer. Therefore, PG has the potential to serve as a risk factor and diagnostic biomarker for breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract